Novel approaches to reproductive medicine and women’s health
At ReproNovo we aim to offer therapies to patients who have difficulties in fulfilling their wish for a successful conception. Driven by this purpose, we are developing first-in-class solutions designed to overcome the limitations of existing treatments in infertility and women’s health.
Our drug development efforts will be concentrated on addressing causes of both male and female infertility, and related fields.
ReproNovo has an exclusive global license agreement with Mereo BioPharma for the development and commercialization of leflutrozole. In addition, ReproNovo has acquired the rights and all assets associated with nolasiban, previously been held by ObsEva. These two compounds have entered ReproNovo’s pipeline as RPN-001 and RPN-002, respectively.
A clinical-stage therapeutic pipeline
RPN-001 (leflutrozole)
With our lead product candidate, RPN-001 (leflutrozole), the focus of our clinical research is on treating infertile men with low serum testosterone. RPN-001 is a novel molecular entity with the potential to enhance spermatogenesis. By inhibiting the aromatase enzyme, leflutrozole suppresses the conversion of testosterone to estradiol, thereby normalizing testosterone levels and rebalancing the testosterone to estradiol ratio. Additionally, it stimulates the production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These effects lead to improved testicular function and increased spermatogenesis.
RPN-002 (nolasiban)
Our second asset RPN-002 (nolasiban) is an oxytocin receptor antagonist. RPN-002 has the potential to increase pregnancy rates and live birth rates in women undergoing embryo transfer after IVF. Clinical studies have demonstrated that blocking oxytocin receptor activation can decrease uterine contractions, increase blood flow to the lining of the uterus and help it better prepare for pregnancy by enhancing its ability to support embryo implantation.
RPN-002 (nolasiban)
With RPN-002, we also aim to develop a treatment for the symptoms of adenomyosis. Adenomyosis is a common uterine condition where tissue from the lining of the uterus grows into the muscular area of the uterus. This condition causes a variety of painful symptoms, including severe menstrual cramps, heavy and prolonged periods, pain during intercourse and difficulties in conceiving. Increased activation of the oxytocin receptor and signaling could play a key role in the development and progression of adenomyosis. Oxytocin receptors are overexpressed in adenomyosis patients, and its levels have been shown to correlate with some of the symptoms. RPN-002 may help alleviate the signs and symptoms of adenomyosis by correcting abnormal uterine contractility, reducing local tissue inflammation, relieving menstrual pain and potentially increase fertility rates.